PeptideDB

KUL-7211 racemate

CAS: 911196-40-2 F: C19H23NO5 W: 345.39

KUL-7211 racemate is the racemate of KUL-7211. KUL-7211 is a selective β-adrenoceptor agonist.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity KUL-7211 racemate is the racemate of KUL-7211. KUL-7211 is a selective β-adrenoceptor agonist[1].
Target β-adrenoceptor
Invitro KUL-7211 is a new β-adrenoceptor agonist in vitro. In rat isolated organs, its selectivities, for inhibition of spontaneous uterine contraction (mediated via β2-adrenergic stimulation) and inhibition of colonic contraction (via β3-adrenergic stimulation) versus increase in atrial rate (via β1-adrenergic stimulation), are 56.3 and 242.2, respectively. KUL-7211 relaxes 80 mM KCl induced tonic contractions in both rabbit (pD2 value: 5.86±0.13, whose ureteral relaxation is mediated via β2-adrenergic stimulation) and canine (pD2 value: 6.52±0.16, via β3-adrenergic stimulation) isolated ureters in a concentration-dependent manner. These KUL-7211-induced relaxing effects are antagonized by ICI-118,551 (selective β2-adrenoceptor antagonist, pKB value: 8.91±0.24) in the rabbit ureter and by bupranolol (non-selective β-adernoceptor antagonist, pKB value: 6.85±0.12) in the canine ureter. KUL-7211 also reduces the spontaneous rhythmic contraction in a canine ureteral spiral preparation in a concentration-dependent manner, the pD2 value being 6.83±0.20. These data clearly demonstrate that KUL-7211 selectively stimulates both ureteral β2- and β3-adrenoceptors and potently relaxes ureteral smooth muscle[1].
Name KUL-7211 racemate
CAS 911196-40-2
Formula C19H23NO5
Molar Mass 345.39
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Tomiyama Y, et al. Pharmacological profile of KUL-7211, a selective beta-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci. 2003 Aug;92(4):411-9.